Effective Date:06/01/2013 |
Title:Intensity Modulated Radiation Therapy (IMRT)
|
Revision Date:03/01/2017
|
Document:BI403:00
|
CPT Code(s):77301, 77338, 77385, 77386, 77418
|
Public Statement
|
Effective Date:
a)
This policy will apply to all services performed on or after the above
revision date which will become the new effective date.
b)
For all services referred to in this policy that were performed before
the revision date, contact customer service for the rules that would apply.
Intensity Modulated Radiation Therapy (IMRT) is a technology for delivering
highly conformal external beam radiation to solid tumors.
This
therapy is considered medically necessary where critical structures cannot be
adequately protected with standard 3-D conformal radiation therapy.
|
Medical Statement
|
IMRT is considered medically necessary for treatment of the following cancers,
when the use of external beam or 3D conformal radiation therapy is likely to
damage surrounding critical structures:
1.
Radiosensitive tumors of the brain, head, neck, spine and Para-spinal
regions
(C00.0-C14.8, C30.0-C32.9,
C41.0-C41.1, C69.00-C72.9, C73, C75.0-C75.3);
or
2.
Pleural mesothelioma
(C45.0)
if
done as a component of a curative treatment regimen; or
3.
Localized prostate cancer
(C61)
when the patient will be treated with dose escalation greater than 75 Gy; or
4.
Anal cancer; or
5.
Anaplastic thyroid cancer; or
6.
Esophageal cancer where dose exceeds 50 Gy; or
7.
Gallbladder cancer where dose exceeds 50 Gy; or
8.
Pancreatic cancer where dose exceeds 50 Gy; or
9.
Head and neck cancer; or
10.
Lymphomas involving the head and neck regions
(C81.01, C81.11, C81.21, C81.31,
C81.41, C81.71, C81.91, C82.01, C82.11, C82.21, C82.31, C82.41, C82.51,
C82.61, C82.81, C82.91, C83.01, C83.11, C83.31, C83.51, C83.71, C83.81,
C83.91, C84.01, C84.11, C84.41, C84.61, C84.71, C84.A1, C84.Z1, C84.91,
C85.11, C85.21, C85.81, C85.91)
11.
Left breast cancer if the lesion is in proximity to cardiovascular
structures; or
12.
Lung cancer if the lesion is in close proximity to critical structures;
or
13.
Postoperative radiation to pelvis for endometrial cancer; or
14.
Cervical cancer.
IMRT requires:
Documentation from Radiation Oncologist that
conventional Radiation therapy will exceed the
safe threshold for normal tissues surrounding the tumor.
Codes Used in
This Policy:
77301 |
Intensity modulated radiotherapy plan, including dose-volume histograms
for target and critical structure partial tolerance specifications |
77338 |
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation
therapy (IMRT), design and construction per IMRT plan |
77385 |
IMRT, simple |
77386 |
IMRT, complex |
77418 |
Intensity modulated treatment delivery, single or multiple fields/arcs,
via narrow spatially and temporally modulated beams, binary, dynamic
MLC, per treatment session
(deleted 1-1-15) |
|
Limits
|
Use of IMRT for
any other indications is considered experimental and investigational and is not
covered.
|
Reference
|
Adams EJ, Nutting CM, Convery DJ, et al. (2001) Potential role of intensity
modulated radiotherapy in the treatment of tumors of the maxillary sinus. Int J
Radiat Oncol Biol Phys 2001; 51:579-88.
Arthur DW, Morris MM, Vicini FA. (2004) Breast cancer: new radiation treatment
options. Oncology 2004; 18:1621-9.
Ashman JB, Zelefsky MJ, et al. (2005) whole pelvic radiotherapy for prostate
cancer using 3D conformal and intensity modulated radiotherapy. Int J Radiat
Oncol Biol 2005; May 20[Epub ahead print].
Bhatnagar AK, Brandner E, et al.(2004) Intensity-modulated radiation therapy
(IMRT) reduces the dose to the contralateral breast when compared to
conventional tangential fields for primary breast irradiation: initial report.
Cancer J 2004; 10:381-5.
Bucci, MK, Bevan, A, Roach III, M. (2005) Advances in Radiation Therapy:
Conventional to 3D, to IMRT, to 4D, and Beyond. CA Cancer J Clin 2005;
55(2):117-34.
Chao KS, Majhail N, Huang CJ, et al.(2001) Intensity modulated radiation therapy
reduces late salivary toxicity without compromising tumor control in patients
with oropharyngeal carcinoma: A comparison with conventional techniques.
Radiother Oncol 2001; 61:275-80.
Cozzi L, Fogliata A, Lomax A, et al.(2001) A treatment planning comparison of 3D
conformal therapy, intensity modulated photon therapy and proton therapy for
treatment of advanced head and neck tumors. Radiother Oncol 2001; 61:287-97.
Eisbruch A, Kim HM, Terrell JE, et al.(2001) Xerostomia and its predictors
following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat
Oncol Biol Phys 2001; 50:695-704.
Guerrero M, Li XA, et al. (2004) Simultaneous integrated boost for breast cancer
using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol
Biol Phys 2004; 59:1513-22.
Guerrero Urbano MT, Nutting CM. (2004) Clinical use of intensity-modulated
radiotherapy: part 1. Br J Radiol 2004; 77:88-96.
Haffty BG, Buchholz TA, McCormick B. (2008) Should IMRT be the standard of care
in the conservatively managed breast care patient. J Clin Oncol, 2008; 26: [epub
2/19/08].
Harris EER, Correa C, Hwang W, et al.(2006) Late Cardiac Mortality and Morbidity
in Early-Stage Breast Cancer Patients After Breast-Conservation Treatment. J
Clin Oncol 2006; 24.
Li JS, Freedman GM, et al. (2004) Clinical implementation of intensity-modulated
tangential beam irradiation for breast cancer. Med Phys 2004; 31:1023-31.
Murshed H, Liu HH, et al. (2004) Dose and volume reduction for normal lung using
intensity-modulated radiotherapy for advanced stage non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys 2004; 58:1258-67.
Nutting CM, Convery DJ, Cosgrove VP, et al.(2001) Improvements in target
coverage and reduced spinal cord irradiation using intensity-modulated
radiotherapy in patients with carcinoma of the thyroid gland. Radiother Oncol
2001; 60:173-80.
Nutting CM, Rowbottom CG, Cosgrove VP, et al. (2001) Optimization of
radiotherapy for carcinoma of the parotid gland: A comparison of conventional,
three dimensional conformal and intensity-modulated technique. Radiother Oncol
2001; 60:163-70.
Patel RR, Das RK. (2006) Image-guided breast brachytherapy: an alternative to
whole-breast radiotherapy. Lancet Oncol 2006; 7:407-15.
Pignol JP, Olivotto I, et al. (2008) A multicenter randomized trial of breast
intensity-modulated radiation therapy to reduce acute radiation dermatitis. J
Clin Oncol, 2008; 26: [epub 2/19/08].
Recht A. (2005) Lessons of Studies of Breast-Conserving Therapy With and Without
Whole-Breast Irradiation for Patient Selection for Partial-Breast Irradiation.
Semin Radiat Oncol 2005; 15:123-132.
Schwartz GF, Veronesi U, Clough KB, et al. (2006) Consensus Conference on Breast
Conservation. American College of Surgeons 2006; 203(2); 198-207.
Taghian AG, Kozak KR, Doppke KP, et al. (2006) Initial dosimetric experience
using simple three-dimensional conformal external-beam accelerated
partial-breast irradiation. Int J Radiat Oncol Biol Phys Mar 15 2006;
64(4):1092-9.
The National Cancer Institute Guidelines for the Use of Intensity-Modulated
Radiation Therapy in Clinical Trials. National Cancer Institute Guidelines;
2005.
Vicini F, Winter K, Straube W, et al. (2005) A phase I/II trial to evaluate
three-dimensional conformal radiation therapy confined to the region of the
lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility
and reproducibility of Radiation Therapy Oncology Group (RTOG) Stu3 Int J Radiat
Oncol Biol Phys 2005; 63(5):1531-7.
Weed DW, Edmundson GK, Vicini FA, et al. (2005) Accelerated partial breast
irradiation: a dosimetric comparison of three different techniques.
Brachytherapy 2005; 4(2):121-9.
Zelefsky MJ, Fuks Z, Hunt M, et al. (2001) High dose radiation delivered by
intensity modulated conformal radiotherapy improves the outcomes of localized
prostate cancer. J Urol 2001:166:876-881.
Addendum:
1.
Effective 03/01/2017:
Added Head and neck region lymphomas as covered diagnosis for IMRT.
|
Application to Products
|
This
policy applies to all health plans and products administered by QualChoice, both
those insured by QualChoice and those that are self-funded by the sponsoring
employer, unless there is indication in this policy otherwise or a stated
exclusion in your medical plan booklet. Consult the individual plan sponsor
Summary Plan Description (SPD) for self-insured plans or the specific Evidence
of Coverage (EOC) or Certificate of Coverage (COC) for those plans or products
insured by QualChoice. In the event of a discrepancy between this policy and a
self-insured customer’s SPD or the specific QualChoice EOC or COC, the SPD, EOC,
or COC, as applicable, will prevail. State and federal mandates will be
followed as they apply.
|
Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
|
|
|